FDA approves J&J’s Inlexzo for high‑risk non‑muscle invasive bladder cancer
Intravesical gemcitabine delivery system cleared as a bladder‑sparing option for patients unresponsive to BCG who decline or cannot undergo cystectomy
The U.S. Food and Drug Administration has approved Johnson & Johnson’s drug delivery system Inlexzo for a form of high‑risk non‑muscle invasive bladder cancer (NMIBC), offering a potential surgery‑sparing treatment for patients who did not respond to Bacillus Calmette‑Guérin (BCG) therapy and who are ineligible for or refuse bladder removal surgery.
The approval was based on data from a mid‑stage study in which more than 82% of patients treated with Inlexzo showed no signs of cancer, and over half remained cancer‑free for at least one year, Johnson & Johnson said. The company described the device as providing sustained, ultra‑low‑dose release of the chemotherapy agent gemcitabine directly into the bladder.
Inlexzo is designed to be inserted directly into the bladder and to remain in place for approximately three weeks per treatment cycle, with patients receiving up to 14 cycles, the company said. J&J said the treatment does not interfere with daily activities and that the most common side effects reported include urinary frequency, urinary tract infections and pain.
"This drug, at ultra low doses for long periods of time… behaves in a way that not only pushes the disease into remission, but then maintains it through some immune memory," Christopher Cutie, vice president and disease area leader for bladder cancer at J&J, said ahead of the FDA decision.
The device was acquired by J&J in 2019 when the company purchased private biotech TARIS Biomedical. J&J is also testing the delivery system in patients with muscle‑invasive bladder cancer, according to the company.
Analysts see a significant commercial opportunity. Guggenheim analyst Vamil Divan estimated potential revenue of about $3.4 billion for Inlexzo by 2040 and described the approval as addressing a ‘‘significant unmet need’’ for patients with limited options after unsuccessful BCG therapy.
BCG immunotherapy is the current standard of care for many patients with NMIBC, but some do not respond to it. For those patients, radical cystectomy — complete removal of the bladder — is often recommended, which can carry major surgical risks and substantially affect quality of life. The FDA clearance positions Inlexzo as an alternative for patients who cannot or will not undergo cystectomy.
Regulatory filings submitted by J&J emphasized the device’s intravesical delivery method, which concentrates gemcitabine in the bladder while limiting systemic exposure. The company presented the mid‑stage study results to regulators as evidence that the system can induce remission and help sustain it through prolonged, localized dosing.
The approval will likely influence treatment discussions between clinicians and patients with BCG‑refractory NMIBC, particularly those seeking bladder‑preserving strategies. Physicians will balance the new option’s reported efficacy and side‑effect profile against longer‑term outcomes and ongoing clinical data.
J&J said it will move to make Inlexzo available to eligible patients following the clearance. The company did not disclose pricing details at the time of the announcement. Regulators approved the device based on the available mid‑stage evidence; additional study data and post‑marketing surveillance will be important to assess durability of response, long‑term safety and performance in broader patient populations.